Who makes Immune System Activator?

Immune System Activator is developed by H. Lundbeck A/S.

What development phase is Immune System Activator in?

Immune System Activator is in Phase 1.

Last reviewed 2026-04-19 · How we verify

Immune System Activator

H. Lundbeck A/S · Phase 1 active Small molecule

At a glance

Generic name	Immune System Activator
Sponsor	H. Lundbeck A/S
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma (PHASE1)
NeoVax With Nivolumab in Patients With Ovarian Cancer (PHASE1)
PBF-1129 in Patients With NSCLC (PHASE1)
A Study Investigating Lu AG22515 in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Immune System Activator CI brief — competitive landscape report
Immune System Activator updates RSS · CI watch RSS
H. Lundbeck A/S portfolio CI